Goldman Sachs’s Ligand Pharmaceuticals LGND Stock Holding History

Goldman Sachs’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-64,120	Closed	-$3.81M	–	5603
2020 Q3	$3.81M	Sell	64,120 -12,183	-16%	-$831K	﹤0.01%	3102
2020 Q2	$5.32M	Buy	+76,303	New	+$4.84M	﹤0.01%	2758
2017 Q2	–	Sell	-25,648	Closed	-$1.69M	–	6869
2017 Q1	$1.69M	Buy	+25,648	New	+$1.69M	﹤0.01%	3917
2014 Q3	–	Sell	-40,075	Closed	-$1.56M	–	7191
2014 Q2	$1.56M	Buy	+40,075	New	+$1.63M	﹤0.01%	4248
2014 Q1	–	Sell	-50,014	Closed	-$1.64M	–	6857
2013 Q4	$1.64M	Buy	50,014 +37,831	+311%	+$1.23M	﹤0.01%	4282
2013 Q3	$329K	Sell	12,183 -67,967	-85%	-$1.91M	﹤0.01%	5499
2013 Q2	$1.87M	Buy	+80,150	New	+$1.44M	﹤0.01%	3793

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Goldman Sachs's LGND Position: Q1 2026 in Review

Goldman Sachs reduced its Ligand Pharmaceuticals (LGND) stake by 11% in Q1 2026, selling an estimated $9.48M and leaving 381,111 shares worth $76.1M. The position accounts for 0.01% of the portfolio, ranked #1237.

Goldman Sachs first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $81.1M in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

Goldman Sachs held 381,111 shares of Ligand Pharmaceuticals worth $76.1M as of Q1 2026.
Goldman Sachs sold 47,893 Ligand Pharmaceuticals shares in Q1 2026, an estimated $9.48M.
Ligand Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1237 holding.
Goldman Sachs first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Ligand Pharmaceuticals position peaked at $81.1M in Q4 2025.
357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.